DexCom stock (NASDAQ: DXCM) currently trades at $73 per share, around 55% below the highs of $163 seen in November 2021. In comparison, Insulet stock (NASDAQ: PODD) saw its stock decline 39% over the ...
StockStory.org on MSN
The 5 most interesting analyst questions from DexCom’s Q4 earnings call
DexCom’s fourth quarter results reflected ongoing momentum in both product innovation and international expansion. Management attributed the quarter’s performance to the broad rollout of the G7 15-day ...
Dexcom is working closely with its insulin pump partners to ensure that Dexcom G7 15 Day will be compatible with automated insulin delivery systems upon launch. Dexcom G7 15 Day is expected to launch ...
DexCom presented outlook on diabetes market at the ADA Conference, highlighting potential for growth with new products like Stelo and DexCom ONE. DexCom's strategy differs from Abbott Labs, focusing ...
DexCom's returns over the past decade have been solid, but not quite on par with the market's. The company has encountered some headwinds in recent years that have sunk its stock price. Despite the ...
Dexcom, the San Diego-based maker of continuous glucose monitors, is moving its local manufacturing operations to Arizona and cutting more than 500 local jobs. Barry Regan, Dexcom’s executive vice ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results